Title: The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey.
Journal: Toxicology and applied pharmacology 20170515
Title: The Role of Neprilysin Inhibitors in Cardiovascular Disease.
Journal: Current heart failure reports 20151201
Title: Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.
Journal: Pharmacotherapy 20150901
Title: Angiotensin-neprilysin inhibition versus enalapril in heart failure.
Journal: The New England journal of medicine 20140911
Title: The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Journal: Lancet (London, England) 20121020
Title: [2 promising substances for diastolic heart failure].
Journal: MMW Fortschritte der Medizin 20120910
Title: Metabolic actions could confound advantageous effects of combined angiotensin II receptor and neprilysin inhibition.
Journal: Hypertension (Dallas, Tex. : 1979) 20110201
Title: Blood-pressure reduction with LCZ696.
Journal: Lancet (London, England) 20100410
Title: Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.
Journal: Lancet (London, England) 20100410
Title: Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).
Journal: Journal of clinical pharmacology 20100401
Title: Ksander GM, et al. Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J Med Chem. 1995 May 12;38(10):1689-700.
Title: Voors AA, et al. The potential role of valsartan + AHU377 ( LCZ696 ) in the treatment of heart failure. Expert Opin Investig Drugs. 2013 Aug;22(8):1041-7.
Title: von Lueder TG, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015 Jan;8(1):71-8.
Title: Hegde, L.G., et al. Comparative efficacy of AHU-377, a potent neprilysin inhibitor, in two rat models of volume-dependent hypertension. BMC Pharmacol 11, P33 (2011).
